HCV Treatment in 2016: Genotypes 1, 2, and 3

Publish date:

October 12, 2016

AETC Source

Objectives

List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.

Presented by:

Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases

Browse more

Languages

English

Topic(s)

Antiretroviral Therapy,

Drug Interactions & Adverse Effects,

Co-occurring Conditions,

Viral Hepatitis Coinfection

Type

Online and Self-Paced Learning

Quick survey

What is your primary profession/discipline

Other Non-Clinical Professional

Other Allied Professional

What is your primary functional role?

Specify Other Role

In what state or territory is your primary worksite?

To what extent have the resources and trainings available through this website increased your knowledge and skills to provide care for people with HIV?

Please indicate if you have used resources and/or trainings from any of the following in the past 12 months.

Select all that apply

Regional AETC Program(s)

National Clinician Consultation Center (NCCC)

National HIV Curriculum (NHC) e-Learning Platform Programs

I am not aware of any of these programs

Approximately what percentage of your patient visits are currently telehealth (phone or video) visits?